Previous 10 | Next 10 |
THE WOODLANDS, Texas, April 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its first quarter 2023 financial results on Tuesday, May 2, 2023 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00 p.m...
2023-04-22 08:15:00 ET Biotech companies yet to generate revenue are some of the riskiest growth stocks out there, but if you can invest in one while it's taking off, your portfolio will thank you. On that note, according to analysts on Wall Street, shares of Lexicon Pharmaceuticals ...
THE WOODLANDS Texas, April 21, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc . (Nasdaq: LXRX), today announced that results from RELIEF-PHN-1, a Phase 2 double-blind, placebo-controlled trial of its investigational drug LX9211 for the treatment of postherpetic neuralgia, will be p...
THE WOODLANDS, Texas, April 17, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced its participation in the 22nd Annual Needham Virtual Healthcare Conference, taking place April 17-20, 2023. Lonnel Coats, Lexicon’s chief executive officer, Jeffrey...
2023-03-07 11:24:57 ET "We do think the [heart failure with preserved ejection fraction (HFpEF)] subpopulation is a relatively attractive opportunity [vs heart failure with reduced ejection fraction (HFrEF)], but having to compete against AstraZeneca's ( AZN ) Farxiga and Eli...
2023-03-05 02:23:39 ET Summary Lexicon is getting closer to FDA approval for sotagliflozin, and the ongoing labeling discussions with the agency may prove critical in differentiating the drug from established rivals. Sotagliflozin may be superior in terms of reducing hospitalizati...
Statistically significant reduction in the risk for the primary outcome on Day 27 Findings generally consistent across the left ventricular ejection fraction (LVEF) range THE WOODLANDS, Texas, March 04, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: ...
Emphasizes challenges faced by patients and clinicians within the first 30 days after discharge from a heart failure hospitalization Reinforces impact of rehospitalizations for heart failure patients and healthcare system Campaign launches at American College of Cardiolo...
Lexicon Pharmaceuticals, Inc. (LXRX) Q4 2022 Earnings Conference Call March 2, 2023 5:00 PM ET Company Participants Carrie Siragusa – Executive Director, Corporate Strategy and Investor Relations Lonnel Coats – Chief Executive Officer Jeff Wade – P...
Lexicon Pharmaceuticals press release ( NASDAQ: LXRX ): Q4 GAAP EPS of -$0.16 misses by $0.03 . Revenue of $0.03M (+200.0% Y/Y) misses by $0.02M . For further details see: Lexicon Pharmaceuticals GAAP EPS of -$0.16 misses by $0.03, revenue of $0.03M misses by $0.02M
News, Short Squeeze, Breakout and More Instantly...
Lexicon Pharmaceuticals Inc. Company Name:
LXRX Stock Symbol:
NASDAQ Market:
Lexicon Pharmaceuticals Inc. Website:
THE WOODLANDS, Texas, July 25, 2024 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) will release its second quarter 2024 financial results on Thursday, August 1, 2024 after the markets close. Management will conduct a conference call and live webcast at 5:00 p.m. ET (4:00...
Launch Preparations Actively Underway; Launch Planned for Early 2025 Lexicon Seeks Approval for Zynquista™ (sotagliflozin) as an Adjunct to Insulin Therapy for Glycemic Control in Adults with Type 1 Diabetes and Chronic Kidney Disease THE WOODLANDS, Texas, July 16, 20...
New analysis of the pivotal Phase 3 SOLOIST-WHF trial provides additional evidence of positive economic impact on hospitals participating in various alternative payment models (APM) Findings consistent with two peer-reviewed studies published in June 2024 THE WOODLANDS, Texa...